Similarly, TRAIL-R2 expression was also associated with trend towards better outcome in the adjuvant treated CRC subgroup (p = 0.0998) but no association with outcome was seen in the group which did not receive adjuvant therapy. The gene discussed is TNFRSF10B; the disease is colorectal carcinoma.